TANGO THERAPEUTICS INC's ticker is and the CUSIP is 87583X109. A total of 119 filers reported holding TANGO THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $24,819,049 | +8.1% | 2,892,663 | 0.0% | 2.72% | +47.6% |
| Q1 2024 | $22,967,744 | -19.8% | 2,892,663 | 0.0% | 1.85% | -32.8% |
| Q4 2023 | $28,637,364 | -12.1% | 2,892,663 | 0.0% | 2.74% | -24.6% |
| Q3 2023 | $32,571,385 | +410.5% | 2,892,663 | +50.5% | 3.64% | +454.3% |
| Q2 2023 | $6,380,343 | +83951.4% | 1,921,790 | 0.0% | 0.66% | -30.8% |
| Q1 2023 | $7,591 | -45.5% | 1,921,790 | 0.0% | 0.95% | -39.0% |
| Q4 2022 | $13,933 | -99.8% | 1,921,790 | 0.0% | 1.56% | +87.6% |
| Q3 2022 | $6,957,000 | -20.1% | 1,921,790 | 0.0% | 0.83% | -18.7% |
| Q2 2022 | $8,706,000 | -40.2% | 1,921,790 | 0.0% | 1.02% | -27.8% |
| Q1 2022 | $14,567,000 | -30.7% | 1,921,790 | 0.0% | 1.42% | -15.1% |
| Q4 2021 | $21,024,000 | -15.4% | 1,921,790 | 0.0% | 1.67% | +8.2% |
| Q3 2021 | $24,849,000 | – | 1,921,790 | – | 1.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP IV, LLC | 19,201,475 | $164,748,656 | 81.48% |
| Mass General Brigham, Inc | 354,192 | $3,038,967 | 14.80% |
| Nextech Invest Ltd. | 5,533,980 | $47,481,548 | 7.99% |
| Boxer Capital, LLC | 8,198,642 | $70,344,348 | 3.70% |
| EcoR1 Capital, LLC | 13,330,736 | $114,377,715 | 3.50% |
| Braslyn Ltd. | 26,961 | $231,325 | 2.77% |
| Bain Capital Life Sciences Investors, LLC | 2,892,663 | $24,819,049 | 2.72% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 115,571 | $991,599 | 1.25% |
| Samsara BioCapital, LLC | 630,000 | $5,405,400 | 1.13% |
| Southpoint Capital Advisors LP | 5,276,699 | $45,274,077 | 1.13% |